文献速递肝病消化道肿瘤与早癌

立体定向体部放疗对比经动脉化疗栓塞或射频消融作为肝细胞癌肝移植桥接治疗的意向性分析

Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
PubMed 文献 · J Hepatol · 2017-02-28

本研究比较立体定向体部放疗(SBRT)、经动脉化疗栓塞(TACE)和射频消融(RFA)作为肝细胞癌肝移植桥接治疗的安全性和有效性。2004年7月至2014年12月共379例患者分别接受SBRT(36例)、TACE(99例)或RFA(244例)。三组脱落率相似,移植后生存率无显著差异,SBRT可安全用作桥接治疗。

要点

  • SBRT组、TACE组和RFA组的脱落率分别为16.7%、20.2%和16.8%,组间相似(p=0.7)。
  • 从等待名单起1、3、5年生存率三组无显著差异(p=0.4)。
  • 从移植时起1、3、5年生存率三组无显著差异(p=0.7)。

核心结论

  • SBRT可安全用于肝细胞癌患者肝移植前的桥接治疗,可作为传统桥接治疗的替代选择。

研究设计与样本

  • 意向性分析,比较2004年7月至2014年12月间接受SBRT(n=36)、TACE(n=99)或RFA(n=244)作为肝移植桥接治疗的379例肝细胞癌患者。

主要发现

  • 脱落率SBRT组16.7% vs TACE组20.2%和RFA组16.8%,p=0.7。
  • SBRT组30例、TACE组79例、RFA组203例接受了移植。
  • 术后并发症三组相似。
  • RFA组移植物中肿瘤坏死更多。
  • 从等待名单起1、3、5年实际生存率:SBRT组83%、61%、61% vs TACE组86%、61%、56% vs RFA组86%、72%、61%,p=0.4。

临床怎么用

  • 作者认为SBRT可安全用作肝细胞癌患者肝移植的桥接治疗,作为传统桥接治疗的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is limited information on the use of stereotactic body radiotherapy (SBRT) as a bridge to liver transplantation for hepatocellular carcinoma and no study comparing its efficacy to transarterial chemoembolization (TACE) and radiofrequency ablation (RFA). We aimed to ascertain the safety and efficacy of SBRT on an intention-to-treat basis compared with TACE and RFA as a bridge to liver transplantation in a large cohort of patients with hepatocellular carcinoma. METHODS: Outcomes between groups were compared from the time of listing and from the time of transplant. Between July 2004 and December 2014, 379 patients were treated with either SBRT (n=36, SBRT group), TACE (n=99, TACE group) or RFA (n=244, RFA group). RESULTS: The drop-out rate was similar between groups (16.7% SBRT group vs. 20.2% TACE group and 16.8% RFA group, p=0.7); 30 patients were transplanted in the SBRT group, 79 in the TACE group and 203 in the RFA group. Postoperative complications were similar between groups. Patients in the RFA group had more tumor necrosis in the explant. The 1-, 3- and 5-year actuarial patient survival from the time of listing was 83%, 61% and 61% in the SBRT group vs. 86%, 61% and 56% in the TACE group, and 86%, 72% and 61% in the RFA group, p=0.4. The 1-, 3- and 5-year survival from the time of transplant was 83%, 75% and 75% in the SBRT group vs. 96%, 75% and 69% in the TACE group, and 95%, 81% and 73% in the RFA group, p=0.7. CONCLUSIONS: In conclusion, SBRT can be safely utilized as a bridge to LT in patients with HCC, as an alternative to conventional bridging therapies. LAY SUMMARY: Patients with liver cancer included in the waiting list for liver transplantation are at risk of tumor progression and death. Stereotactic body radiotherapy may be a good alternative to conventional therapies to reduce this risk.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017. PMID: 28257902. doi:10.1016/j.jhep.2017.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。